Adlai Nortye Group Ltd.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About Adlai Nortye
Pharmaceutical Preparations, SIC 2834
Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company that focuses on the discovery and development of innovative drug candidates. The company engages in preclinical research and clinical trials to evaluate therapeutic treatments for targeted diseases. Its operations encompass experimental pharmaceutical therapies designed to address conditions regulated by health agencies such as the United States Food and Drug Administration and the National Medical Products Administration. Its prospective end users are patients suffering from targeted illnesses.
The company maintains its principal executive offices in Grand Cayman, Cayman Islands, with approved plans to redomicile to Singapore. Daily operations are primarily conducted through operating subsidiaries in the United States and mainland China, supported by affiliated entities in Hong Kong, Singapore, and Switzerland. The organization maintains a corporate contact office in North Brunswick, New Jersey, while its Chinese operations include entities in Hangzhou and Shanghai.
Summary of the business section of Adlai Nortye's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Adlai Nortye Group Ltd.
- Headquarters
- Singapore, Singapore
- Address
- 77 Robinson Road, #20-01, Robinson 77 068896
- Phone
- (848) 230-7430
- Website
- adlainortye.com
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- BDO China Shu Lun Pan Certified Public Accountants LLP, Shanghai, The Peoples Republic of China
Stock & identifiers
- Ticker
- ANL
- Exchange
- Nasdaq
- IPO date
- Sep 29, 2023
- Shares outstanding
- 120M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Emerging growth company
- SEC CIK
- 1944552
- CUSIP
- 00704R109
- ISIN
- US00704R1095
- LEI
- 54930009TDXE4YQVKU60
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Yang Lu | CEO, Director | 17,089,990 |
| Xiaofeng Ye | CFO | 147,788 |
| Archie Tse | President, Head of R&D | 50,000 |
| Kaiyang Tang | President,Adlai Nortye USA INC | – |
| Ping Ji | Director | 131,667 |
| Lars Erik Birgerson | Director | 166,668 |
| Roger Sawhney | Director | 9,838 |
| Alan Ming Lun Tse | Director | – |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 19, 2026 | Name change | Name changed from Adlai Nortye Ltd. to Adlai Nortye Group Ltd. |
| Sep 29, 2023 | IPO | Initial public offering priced (424B4 prospectus) |
| Aug 18, 2023 | Listing | Registration of securities on an exchange (Form 8-A) |
| Aug 7, 2023 | Listing | Registration of securities on an exchange (Form 8-A) |